GlassScriptPhysician profile
Vipul K Parikh
NPI 1518982958
$3,197.24
in general payments reported to CMS, 2019-2025
31 companies · $660 in 2025
The $660 reported for 2025 was more than what 83% of Geriatric Medicine (Internal Medicine) providers received nationally (typical 2025 total: $123).
See the full distribution for Geriatric Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $78.37 · 2021: $310 · 2022: $319 · 2023: $446 · 2024: $1,385 · 2025: $660.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,490.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,490.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,336.38 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $447.06 | 2020-2025 | Trelegy Ellipta |
| Boston Scientific Corporation | $210.26 | 2022-2023 | Watchman Flx |
| Silk Road Medical, INC. | $122.03 | 2023 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent |
| Becton, Dickinson and Company | $120.81 | 2024 | Phasix Mesh |
| Sumitomo Pharma America, INC. | $101.85 | 2024-2025 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $79.66 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $68.49 | 2023-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $68.28 | 2020-2022 | |
| Novo Nordisk INC | $57.74 | 2020-2023 | Rybelsus, Ozempic |
| Neurocrine Biosciences, INC. | $54.27 | 2025 | |
| Baxter Healthcare | $52.64 | 2025 | Hillrom - Carnation Ambulatory Monitor |
| Abbvie INC. | $47.81 | 2020-2025 | |
| Lilly USA, LLC | $44.37 | 2021-2024 | Mounjaro |
| Novartis Pharmaceuticals Corporation | $41.28 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viatris Specialty LLC | $39.34 | 2025 | Yupelri |
| Philips North America LLC | $36.76 | 2024 | (Ak6) Vest Therapy |
| Pfizer INC. | $35.66 | 2023-2025 | |
| Sunovion Pharmaceuticals INC. | $27.28 | 2021-2022 | |
| Strongbridge US INC. | $26.40 | 2020 | |
| Abbott Laboratories | $22.27 | 2023 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.84 | 2025 | Jascayd |
| Vanda Pharmaceuticals INC. | $17.89 | 2025 | Fanapt |
| Teva Pharmaceuticals USA, INC. | $17.77 | 2025 | Austedo Xr |
| Aimmune Therapeutics, INC. | $16.85 | 2024 | |
| Paratek Pharmaceuticals, INC. | $16.70 | 2025 | Nuzyra, Xhance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.16 | 2025 | Caplyta |
| Sun Pharmaceutical Industries INC. | $14.27 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $13.49 | 2025 | Eliquis |
| Dexcom, INC. | $13.27 | 2021 | |
| Avanir Pharmaceuticals, INC. | $11.36 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vipul Parikh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.